YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Femasys Inc. (FEMY) announced that it has entered into a securities purchase agreement for a $30 million private placement of shares and warrants led by Nantahala Capital. Under the terms of the agreement, Femasys is selling to…
(RTTNews) - Today's top biotech gainers include Wellgistics following its rebranding, Femasys, which recently resolved its Nasdaq compliance issue, Vor Bio with continued progress in its Telitacicept program, and Sol-Gel Technologies as in…
(RTTNews) - Femasys Inc. (FEMY) announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the matter with regulators and securing continued listing status. Chief Executive Officer Kathy Lee-Sepsick called th…
Key Points Dauntless Investment Group bought 116,863 shares of Innoviva in an estimated trade of $2.52 million last quarter. The quarter-end position value rose by $2.74 million, reflecting both trading and price movements. The post-trade…
ATLANTA, May 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announces its financial…
Femasys Inc. ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwid…
ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has…
(RTTNews) - Several biotech and healthcare stocks posted notable gains in after-hours trading on Friday, driven by regulatory developments, financing updates, and investor sentiment. Atossa Therapeutics, Inc. (ATOS) rose 12.98% to $0.69, u…
Femasys Inc. ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective t…
(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Halozy…
– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Femasys Inc…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change MSP Recovery Inc. 437,923,706 0.8807 0.52 0.7959 +0.5759 EZGO Technologies…
--Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- --$12 million senior secured convertible notes for total potential proceeds…
(RTTNews) - Biotech stocks led the after-hours charge on Thursday, with Inhibrx Biosciences (INBX) skyrocketing over 81% on positive Phase 2 trial results in chondrosarcoma. Femasys (FEMY), Cingulate (CING), and Community Health Systems (C…
SAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, is pleased t…
ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the introduc…
ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced it has recei…
We recently published 10 Stocks Losing Big. Femasys Inc. (NASDAQ:FEMY) is one of the worst performers of Tuesday. Femasys extended losses to a second day on Tuesday, slashing 27 percent to close at $0.3760 apiece as investor sentiment was…
(RTTNews) - Femasys Inc. (FEMY) has priced an underwritten public offering totaling approximately $8 million through the sale of 10.43 million shares of common stock or pre-funded warrants, along with common warrants to purchase up to 22.1…
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 90.28% INVIVYD INC'S (NASDAQ:IVVD [http…
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT NUKKW [https://www.chartmill.com/st…
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT HKPD [https://www.chartmill.com/stock/quote/HKP…
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. [premarket] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 132.0% Investors witnessed a remarkable su…
Femasys (NASDAQ:FEMY [https://seekingalpha.com/symbol/FEMY]) has announced a public offering [https://seekingalpha.com/pr/20210917-femasys-announces-pricing-of-8_0-million-underwritten-public-offering] to raise approximately $8.0 million,…
ATLANTA - Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on women’s health with a market capitalization of $16.8 million, announced Monday the pricing of an underwritten public offering expected to raise approximately $8 million…
ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, acces…
* Femasys press release [https://seekingalpha.com/pr/20195248-femasys-announces-second-quarter-financial-results-for-2025] (NASDAQ:FEMY [https://seekingalpha.com/symbol/FEMY]): Q2 GAAP EPS of -$0.16. * Sales increased by $187,784, or 84.8%…
Key Points Revenue surged 84.8% to $0.41 million (GAAP) in Q2 2025, far outpacing consensus estimates (GAAP) but still early-stage in scale. FemBloc gained its first-ever European approval; FemaSeed and FemVue secured new regulatory cleara…
-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical p…
* Femasys (NASDAQ:FEMY [https://seekingalpha.com/symbol/FEMY]) on Wednesday announced its entry into Europe with an order of about $400,000 for FemBloc Permanent Birth Control in Spain. * FemBloc is a non-surgical solution for permanent bi…
-- Femasys continues to expand access and market share for its first-line infertility treatment option, FemaSeed® -- ATLANTA, June 11, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing signif…
* Femasys (NASDAQ:FEMY [https://seekingalpha.com/symbol/FEMY]) on Friday announced the pricing of an underwritten public offering of 3.6M shares of its common stock at a public offering price of $0.85 per share and a separate concurrent pr…
* Femasys (NASDAQ:FEMY [https://seekingalpha.com/symbol/FEMY]) plans to sell common stock in an underwritten public offering. A 30-day option will be granted to underwriters to purchase up to 15% additional shares. * All securities in both…
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, access…
-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- AT…
-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ…